The Comorbidity of Chronic Obstructive Pulmonary Disease and Peripheral Artery Disease – A Systematic Review

Kaszuba, Marek; Śliwka, Agnieszka; Piliński, Rafał; Kościelniak, Jolanta; Maga, Paweł; Bochenek, Grażyna; Nowobilski, Roman

doi:10.1080/15412555.2019.1653271

Cited by 6 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intriguingly, in multivariate regression analyses, the COSYCONET investigators demonstrated that PAD was independently associated with impaired diffusion capacity, besides the well-known risk factors of PAD (older age, current smoking, hypercholesterolemia, hypertension, and diabetes). [20] In our study result suggests an association between emphysema and PAD, and is in line with the association between coronary artery calcifications and emphysema severity. [21] The vascular etiology hypothesis of COPD posits that emphysema is mainly caused by the destruction of pulmonary capillaries, leading to loss of alveolar walls, and considers emphysema primarily a small-vessel disease (i.e., microangiopathy).…”

Section: Discussionsupporting

confidence: 91%

“…Patients with COPD and comorbid PAD had a more impaired functional capacity because the 6-minute-walk distance was significantly lower compared with those without PAD, even after correcting for confounders such as age and smoking status. [20] Importantly, patients with COPD and comorbid PAD had worse disease-specific health status as assessed with the COPD-specific St. George' s Respiratory Questionnaire. Intriguingly, in multivariate regression analyses, the COSYCONET investigators demonstrated that PAD was independently associated with impaired diffusion capacity, besides the well-known risk factors of PAD (older age, current smoking, hypercholesterolemia, hypertension, and diabetes).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association between Chronic Obstructive Pulmonary Disease and Peripheral Arterial Disease in Construction Workers-A Cross-Sectional Study

Sivakumar¹,

Garg²,

Nighute³

2021

PJMHS

View full text Add to dashboard Cite

Objective: COPD has been recognized not only as a lung but also a systemic disease. Smoking is a major cause of COPD, cardiovascular disease, stroke and peripheral arterial disease (PAD). Methods: This was a cross-sectional study conducted at the Department of Physiology, Santosh Medical College diagnosed with COPD using Spirometry was recruited for the study with a sample size of 130 patients. Results: Of the 130 participants, the mean age was 51.73 years of all COPD patients. Thirty-seven (28.46%) were diagnosed to have PAD. Twenty-five patients (19.23%) were overweight, 10 (7.69%) were obese. All the patients included in the study had history of smoking, including current (n= 67, 51.5%) and former (n= 35, 26.9%) smokers. There was no patient with severe respiratory failure in our study. The most common cardiovascular co-morbidity was hypertension (n= 67, 51.5%), followed by diabetes mellitus (n =28, 21.5%), and dyslipidaemia (n= 35, 26.92%). PAD seen in different stages of COPD stage I –IV were 2.94%, 55.88%, 61.76%, 20.58% respectively. Conclusion: The diagnosis of peripheral arterial disease in COPD is important because this is an entity that limits the patient’s physical activity and impairs their quality of life. Lung function was not associated with PAD in patients with COPD. Abnormal ABI results were associated with a higher prevalence of risk factors and more severe lung disease. Keywords: Peripheral Arterial Disease, Smoking, Chronic Obstructive Pulmonary Disease.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Association between Chronic Obstructive Pulmonary Disease and Peripheral Arterial Disease in Construction Workers-A Cross-Sectional Study

Sivakumar¹,

Garg²,

Nighute³

2021

PJMHS

View full text Add to dashboard Cite

show abstract

“…The few prior studies of patients with concomitant PAD and COPD have focused on mortality, which they reported was higher in this population, consistent with our data. 11,12 Our analysis adds depth and nuance to these findings, showing that the increase in all-cause mortality is not due to cardiovascular mortality, while patients with COPD are also at significantly greater risk of other clinically-important events. Patients with COPD in addition to PAD carry an increased risk of MACE driven by significantly higher risks of MI, specifically type 2 MI, as well as increased risks of all-cause and respiratory-related hospitalizations.…”

mentioning

confidence: 78%

Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial

Galani¹,

Mulder²,

Rockhold³

et al. 2021

COPD

View full text Add to dashboard Cite

Background: Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of developing lower extremity peripheral artery disease (PAD) and suffering PADrelated morbidity and mortality. However, the effect and burden of COPD on patients with PAD is less well defined. This post hoc analysis from EUCLID aimed to analyze the risk of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in patients with PAD and concomitant COPD compared with those without COPD, and to describe the adverse events specific to patients with COPD. Methods: EUCLID randomized 13,885 patients with symptomatic PAD to monotherapy with either ticagrelor or clopidogrel for the prevention of MACE. In this analysis, MACE, MALE, mortality, and adverse events were compared between groups with and without COPD using unadjusted and adjusted Cox proportional hazards model. Results: Of the 13,883 patients with COPD status available at baseline, 11% (n=1538) had COPD. Patients with COPD had a higher risk of MACE (6.02 vs 4.29 events/100 patientyears; p<0.001) due to a significantly higher risk of myocardial infarction (MI) (3.55 vs 1.85 events/100 patient-years; p<0.001) when compared with patients without COPD. These risks persisted after adjustment (MACE: adjusted hazard ratio (aHR) 1.30, 95% confidence interval [CI] 1.11-1.52; p<0.001; MI: aHR 1.45, 95% CI 1.18-1.77; p<0.001). However, patients with COPD did not have an increased risk of MALE or major bleeding. Patients with COPD were more frequently hospitalized for dyspnea and pneumonia (2.66 vs 0.9 events/ 100 patient-years; aHR 2.77, 95% CI 2.12-3.63; p<0.001) and more frequently discontinued study drug prematurely (19.36 vs 12.54 events/100 patient-years; p<0.001; aHR 1.34, 95% CI 1.22-1.47; p<0.001). Conclusion:In patients with comorbid PAD and COPD, the risks of MACE, respiratoryrelated adverse events, and premature study drug discontinuation were higher when compared with patients without COPD. Registration: ClinicalTrials.gov: NCT01732822.

show abstract

“…In another recent systematic review, based on six studies with diagnostic confirmation of PAOD with ABI and COPD with spirometry, COPD patients with PAOD were more frequently males with tobacco history, hypertension, dyslipidemia, higher values of fibrinogen and C-reactive protein, lower values of FEV 1 %, and higher dyspnea levels. 75…”

Section: Systematic Reviews and Meta-analysismentioning

confidence: 99%

“…A number of primary studies of the effect of PAOD in COPD patients have been published and included in systematic reviews and meta-analysis, 6,75 but a recent study sought to investigate the incidence of PAOD among COPD patients in Taiwan using a national database reports interesting data. In this study, 51,869 COPD patients were collected from the National Health Insurance Research Database of Taiwan from 1996 to 2010 and compared with the same number of controls without COPD.…”

Section: Primary Studiesmentioning

confidence: 99%

<p>Insights into Chronic Obstructive Pulmonary Disease as Critical Risk Factor for Cardiovascular Disease</p>

Almagro¹,

Boixeda²,

Díez-Manglano³

et al. 2020

COPD

View full text Add to dashboard Cite

In patients with chronic obstructive pulmonary disease (COPD), cardiovascular comorbidities are highly prevalent and associated with considerable morbidity and mortality. This coincidence is increasingly seen in the context of a "cardiopulmonary continuum" rather than being simply attributed to shared risk factors, in particular, cigarette smoking. Both disease entities are centrally linked to systemic inflammation as well as aging, arterial stiffness, and several common biomarkers that led to the development of pulmonary hypertension, left ventricular diastolic dysfunction, atherosclerosis, and reduced physical activity and exercise capacity. For these reasons, COPD should be considered an independent factor of high cardiovascular risk, and efforts should be directed to early identification of cardiovascular disease (CVD) in COPD patients. Assessment of the overall cardiovascular risk is especially important in patients with severe exacerbation episodes, and the same therapeutic target levels for glycosylated hemoglobin, low-density lipoprotein cholesterol (LDL-C), or blood pressure than those recommended by clinical practice guidelines for patients at high cardiovascular risk, should be achieved. In this review, we will discuss the most recent evidence of the role of COPD as a critical cardiovascular risk factor and try to find new insights and potential prevention strategies for this disease.

show abstract

The Comorbidity of Chronic Obstructive Pulmonary Disease and Peripheral Artery Disease – A Systematic Review

Cited by 6 publications

References 19 publications

Association between Chronic Obstructive Pulmonary Disease and Peripheral Arterial Disease in Construction Workers-A Cross-Sectional Study

Association between Chronic Obstructive Pulmonary Disease and Peripheral Arterial Disease in Construction Workers-A Cross-Sectional Study

Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial

<p>Insights into Chronic Obstructive Pulmonary Disease as Critical Risk Factor for Cardiovascular Disease</p>

Contact Info

Product

Resources

About